The putative oncogene CPI‐17 is up‐regulated in schwannoma
- 27 November 2016
- journal article
- Published by Wiley in Neuropathology and Applied Neurobiology
- Vol. 42 (7) , 664-668
Abstract
No abstract availableKeywords
Funding Information
- Deutsche Forschungsgemeinschaft (GRK 1715/1, MO 1421/2-1)
- Deutsche Krebshilfe (DKH 109584)
- Children's Tumor Foundation (2015-05-010)
This publication has 13 references indexed in Scilit:
- NF2 Genetic Alterations in Sporadic Vestibular SchwannomasOtology & Neurotology, 2013
- Nuclear localization of CPI-17, a protein phosphatase-1 inhibitor protein, affects histone H3 phosphorylation and corresponds to proliferation of cancer and smooth muscle cellsBiochemical and Biophysical Research Communications, 2013
- Hybrid Neurofibroma/Schwannoma is Overrepresented Among Schwannomatosis and Neurofibromatosis PatientsAmerican Journal of Surgical Pathology, 2012
- Pathology of peripheral nerve sheath tumors: diagnostic overview and update on selected diagnostic problemsActa Neuropathologica, 2012
- Rates of loss of heterozygosity and mitotic recombination in NF2 schwannomas, sporadic vestibular schwannomas and schwannomatosis schwannomasOncogene, 2010
- Bevacizumab induces regression of vestibular schwannomas in patients with neurofibromatosis type 2Neuro-Oncology, 2009
- Functional inactivation of NF2/merlin in human mesotheliomaLung Cancer, 2009
- Tumorigenic transformation by CPI-17 through inhibition of a merlin phosphataseNature, 2006
- Diagnostic criteria for schwannomatosisNeurology, 2005
- NeurofibromatosisArchives of Neurology, 1988